Safety And Efficacy Sublingual Misoprostol Versus Vaginal Misoprostol.

Phase 3

• Conditions: Labour induction outcome

• Registration Number: PACTR202310744034060
• Lead Sponsor: Dr. Aituma Lewis Osadebamwen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-09-30
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 82

Inclusion Criteria

Prigravida
Gestational age =37 to 42 weeks.
Participants who have indication for induction of Labour.
Cervical assessment with Modified Bishops score value of less than 6.
Singleton gestation.
Cephalic presentation.
Optimal biophysical profile.
Participants who gave written consent to participate in the study.

Exclusion Criteria

Teenage pregnancy.
Participants who withdraw consent even after being enrolled into the sudy.
All indications for Cesarean section.
Participants with relative or absolute contraindications to misoprostol use (e.g.; misoprostol allergies, Acute Cerebrovascular Disease, Coronary Artery Disease, epileptics).
A history of extensive uterine surgery.
Abnormal vaginal bleeding.
An unconscious patient.

Study & Design

• Study Type: Interventional
• Study Design: Not specified